poisar

Stocks · News reference

This Shattuck Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

BenzingaJul 24, 2026, 1:29 PMAvi Kapoor

Wall Street analysts changed outlook on top names. For full changes, upgrades, downgrades and initiations, see analyst ratings page.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Jul 24, 2026, 1:29 PM
Checked
Jul 24, 2026, 1:29 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolAug 27, 2026, 7:37 PMBrendan Coffey

    Archer Aviation vs. Space Exploration Technologies: Which High Flying Stock Is a Better Buy in 2026?

    Archer Aviation and SpaceX represent two different aerospace plays with vastly different maturity levels. Archer is pre-commercial with $300K revenue and $618M losses, pursuing FAA certification for eVTOL aircraft. SpaceX generates $18.7B in revenue but reported a $5B net loss in FY2025 due to massive capital requirements. The article concludes SpaceX is the wiser long-term choice despite both companies' negative cash flows, citing SpaceX's established Starlink business and market support versus Archer's high valuation multiples and regulatory uncertainties.

    Read original at the-motley-fool
  2. The Motley FoolAug 24, 2026, 10:03 PMEric Volkman

    What Shattuck Labs Stock Topped the Market on Monday

    Shattuck Labs (STTK) gained nearly 5% on Monday following positive analyst coverage from two firms. TD Cowen initiated a buy rating while Raymond James issued a strong buy with an $18 price target (more than double the $7.90 closing price). The optimism centers on the company's lead drug candidate SL-325, a first-in-class autoimmune and inflammatory disease treatment currently in Phase 2b clinical testing for inflammatory bowel disease, with analysts estimating a $20+ billion addressable market.

    Read original at the-motley-fool